Multi-drug approaches to NASH: what’s in the development pipeline?
- 23 September 2019
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 29 (2) , 143-150
Abstract
Introduction The pandemic of obesity over the last two decades has triggered a rise in prevalence of non-alcoholic fatty liver disease (NAFLD). NAFLD is associated with liver-related- and cardiovascular complications. Despite this, the first licensed drug for NAFLD is yet to be approved. Given the scale of the problem and unmet needs, there is a myriad of agents in the development pipeline. Areas covered We discuss promising agents in early phase clinical trials and categorize these agents based on their action on steatosis, steatohepatitis and fibrosis. Furthermore, given the multisystemic nature of NAFLD, we consider the effects of these agents on the liver, their cardiometabolic effects, and the potential future strategies of combination therapies. Expert opinion The paradigm for the ideal drug is the targeting of both steatohepatitis and fibrosis and the amelioration of cardiometabolic risk factors. New drugs that confer benefit in NASH, must also be tested for their effects on T2DM and CVD. The treatment of NASH will become analogous to the treatment of hypertension; it is very likely that multiple classes of drugs targeting different mechanistic pathways will be necessary because no single agent is likely to control all aspects of this complex liver disease.Keywords
This publication has 30 references indexed in Scilit:
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trialThe Lancet, 2015
- Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic targetExpert Opinion on Therapeutic Targets, 2014
- The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 DiabetesCell Metabolism, 2013
- Thyroid hormone receptor-β agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathwaysAmerican Journal of Physiology-Endocrinology and Metabolism, 2013
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological AssociationHepatology, 2012
- The role of thiazolidinediones in non-alcoholic steatohepatitis – A systematic review and meta analysisJournal of Hepatology, 2011
- Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adultsAlimentary Pharmacology & Therapeutics, 2011
- Roles of FGF19 in Liver MetabolismCold Spring Harbor Symposia on Quantitative Biology, 2011
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2010
- A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2006